Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 20/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9046607 | 0.92 | ALOX5 (0.68) | ALOX5 | |
| SCHEMBL6024923 | 0.91 | ALOX5 (0.64) | ALOX5 | |
| SCHEMBL9035232 | 0.87 | ALOX5 (0.70) | ALOX5PTGS1PTGS2 | |
| SCHEMBL9029002 | 0.87 | ALOX5 (0.70) | ALOX5PTGS1PTGS2 | |
| SCHEMBL9074032 | 0.86 | ALOX5 (0.63) | ALOX5PTGS1PTGS2 | |
| SCHEMBL9074025 | 0.86 | ALOX5 (0.63) | ALOX5PTGS1PTGS2 | |
| SCHEMBL9074027 | 0.86 | ALOX5 (0.63) | ALOX5PTGS1PTGS2 | |
| SCHEMBL9253013 | 0.85 | ALOX5 (0.70) | ALOX5PTGS1PTGS2 | |
| SCHEMBL9037639 | 0.85 | ALOX5 (0.74) | ALOX5PTGS1PTGS2 | |
| SCHEMBL7535396 | 0.84 | ALOX5 (0.61) | ALOX5PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998415-B2 | Pyrazolyl derivatives; antiinflammatory agents for inflammation; antiallergens for asthma | PHARMACIA CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040147565-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. | 2004-07-29 | — | — | US | disclosed |
| US-6677364-B2 | ANTI-INFLAMMATORY, ANTIPYRETIC, ANALGESIC COMPOSITIONS | G.D. SEARLE & CO. | 2004-01-13 | — | — | US | disclosed |
| EP-0828736-B1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0995747-B1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | SEARLE & CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020086886-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. | 2002-07-04 | — | — | US | disclosed |
| EP-0995747-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0828736-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996038442-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147565-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | ALOX5 1/4885PTGS1 9/4885PTGS2 6/4885 |
| US-20020086886-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, PTGES2, PTGS2 | ALOX5 1/4885PTGS1 8/4885PTGS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.